These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21279328)

  • 1. Validity and reliability of patient selected goals as an outcome measure in overactive bladder.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    Int Urogynecol J; 2011 Jul; 22(7):841-7. PubMed ID: 21279328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms.
    Lee KS; Lee YS; Kim JC; Seo JT; Lee JZ; Choo MS
    Int J Clin Pract; 2012 Jul; 66(7):663-70. PubMed ID: 22698418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 May; 107(10):1612-7. PubMed ID: 21070569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women.
    Gittelman M; Weiss H; Seidman L
    J Urol; 2014 Apr; 191(4):1014-21. PubMed ID: 24231837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
    Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
    J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.
    Wang AC; Chih SY; Chen MC
    Urology; 2006 Nov; 68(5):999-1004. PubMed ID: 17113893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder.
    Barsdorf AI; Carlsson M; Bushmakin AG; Quinn S; Cappelleri JC; Pleil A
    Int Urogynecol J; 2017 Dec; 28(12):1857-1863. PubMed ID: 28378111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and psychometric evaluation of the urgency questionnaire for evaluating severity and health-related quality of life impact of urinary urgency in overactive bladder.
    Coyne KS; Sexton CC; Thompson C; Bavendam T; Brubaker L
    Int Urogynecol J; 2015 Mar; 26(3):373-82. PubMed ID: 24942375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
    Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
    J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
    Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin.
    Müller-Arteaga C; Batista-Miranda JE; Zubiaur Libano C; El Khoury Moreno R; Morales Solchaga G; Casas Nebra J; Leva Vallejo M; Gonzalez Garcia O; Errando-Smet C; Arlandis-Guzman S
    Actas Urol Esp (Engl Ed); 2019 Apr; 43(3):143-150. PubMed ID: 30470585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal oxybutynin.
    Baldwin CM; Keating GM
    Drugs; 2009; 69(3):327-37. PubMed ID: 19275276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considering the prominent complaint as a guide in medical therapy for overactive bladder syndrome in women over 45 years.
    Jafarabadi M; Jafarabadi L; Shariat M; Rabie Salehi G; Haghollahi F; Rashidi BH
    J Obstet Gynaecol Res; 2015 Jan; 41(1):120-6. PubMed ID: 25369726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
    Sand PK; Davila GW; Lucente VR; Thomas H; Caramelli KE; Hoel G
    Am J Obstet Gynecol; 2012 Feb; 206(2):168.e1-6. PubMed ID: 21963104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
    Choo MS; Doo CK; Lee KS
    Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prominent complaint: a guide to medical therapy of overactive bladder syndrome in older women.
    Jafarabadi M; Ghanbari Z; Hashemi S; Nemati M; Haghollahi F; Azimi Nekoo E
    Acta Med Iran; 2015; 53(2):125-8. PubMed ID: 25725183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gelnique (oxybutynin chloride) 10% gel for overactive bladder.
    Lajiness MJ
    Urol Nurs; 2010; 30(4):253-4. PubMed ID: 20949812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.